Your browser doesn't support javascript.
loading
Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia.
Tabah, Ashley; Huggar, David; Wang, Si-Tien; Johnson, Scott J; Copher, Ronda M; O'Connell, Thomas; McBride, Ali; LeBlanc, Thomas W.
Afiliación
  • Tabah A; US HEOR, Bristol Myers Squibb, Summit, NJ 07901, USA.
  • Huggar D; US HEOR, Bristol Myers Squibb, Summit, NJ 07901, USA.
  • Wang ST; Medicus Economics, LLC., Boston, MA 02186, USA.
  • Johnson SJ; Medicus Economics, LLC., Boston, MA 02186, USA.
  • Copher RM; US HEOR, Bristol Myers Squibb, Summit, NJ 07901, USA.
  • O'Connell T; Medicus Economics, LLC., Boston, MA 02186, USA.
  • McBride A; US HEOR, Bristol Myers Squibb, Summit, NJ 07901, USA.
  • LeBlanc TW; Duke University School of Medicine, Durham, NC 27705, USA.
Future Oncol ; 2022 Dec 12.
Article en En | MEDLINE | ID: mdl-36507931
Older people with acute myeloid leukemia (AML) may have remission with or without blood count recovery, after first-line chemotherapy; however, remission is short lived and overall survival is limited (7­12 months). Ongoing treatment (maintenance therapy) after response to initial chemotherapy may prolong remission. Maintenance therapy with azacitidine (AZA) given by injection beneath the skin (subcutaneous) or into a vein (intravenous) can extend disease-free survival compared with no further treatment and best supportive care. However, treatment with intravenous AZA may only extend overall survival in certain patients. ONUREG® is a novel formulation of AZA that can be taken by mouth (orally), remains in the body for longer periods and has the potential for significant clinical benefits compared with intravenous AZA. Presently, there are no studies directly comparing outcomes of maintenance therapy with oral and injectable AZA in older people with AML. In this analysis, we used an indirect treatment comparison method including four clinical trials to explore the survival benefit associated with ONUREG and injectable AZA when used as maintenance therapies after response to initial chemotherapy in older people with AML. Findings showed ONUREG significantly improved overall survival compared with injectable AZA, with an almost 26% reduction in the risk of death. These results suggest that maintenance therapy with ONUREG significantly improves overall survival compared with injectable AZA in older people with AML who may have remission with or without blood count recovery, after first-line chemotherapy.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Future Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Future Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido